Eli Lilly and Company ($LLY) Stock Forecast: Up 5.0% Today

What is Eli Lilly and Company?

Eli Lilly (NYSE: LLY) is a pharmaceutical company known for its innovative healthcare solutions. Today, the stock experienced a strong bullish movement amidst significant news developments.

Why is Eli Lilly and Company going up?

LLY stock is up 5.0% on Aug 26, 2025 19:25

• Eli Lilly stock surged after positive results from its oral GLP-1 pill trial, which demonstrated impressive weight loss benefits and blood sugar level reductions.
• The success of the weight-loss pill trial has fueled investor optimism and confidence in Eli Lilly's future growth prospects.
• Despite a setback with its orforglipron pill, the company's robust late-stage pipeline continues to support expectations for sustained growth and innovation in the pharmaceutical sector.
• The investigation by the Portnoy Law Firm into Eli Lilly's activities does not seem to have impacted the stock's bullish momentum, indicating that investors are primarily focused on the positive trial results and growth potential.

LLY Price Chart

LLY Technical Analysis

LLY News

Eli Lilly Stock Jumps On Weight-Loss Pill Trial - Eli Lilly ( NYSE:LLY )

Lilly stock pops after its oral GLP-1 pill helped patients lose an average of 10.5% of their body weight. The GLP-1 oral pill also reduces blood sugar levels and meets key goals in Lilly's pivotal Phase 3 trial. See the 6X seasonal strategy set to target this fall's biggest opportunities.

https://www.benzinga.com/markets/biotech/25/08/47340438/eli-lilly-stock-jumps-on-weight-loss-pill-trial

Why Is Eli Lilly Stock Soaring Tuesday? - Eli Lilly ( NYSE:LLY )

Orforglipron cut body weight by 10.5% at 72 weeks, compared to 2.2% with placebo. 75% of patients on the top dose achieved A1C ≤6.5%, per ADA diabetes standards. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →

https://www.benzinga.com/news/health-care/25/08/47330300/eli-lillys-obesity-pill-shows-big-wins-in-weight-blood-sugar-and-heart-risk-factors

$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today - Eli Lilly ( NYSE:LLY )

Eli Lilly LLY has outperformed the market over the past 15 years by 9.64% on an annualized basis producing an average annual return of 22.48%. Currently, Eli Lilly has a market capitalization of $637.57 billion.

https://www.benzinga.com/insights/news/25/08/47293215/1000-invested-in-eli-lilly-15-years-ago-would-be-worth-this-much-today

Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.

https://www.zacks.com/stock/news/2741315/is-orforglipron-pill-setback-end-of-the-road-for-llys-obesity-plans

Eli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm - Eli Lilly ( NYSE:LLY )

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Eli Lilly and Company ( "Eli Lilly" or "the Company" ) LLY investors that the firm has initiated an investigation into possible ...

https://www.benzinga.com/pressreleases/25/08/g47272078/eli-lilly-and-company-investors-company-investigated-by-the-portnoy-law-firm

Trending Today

Eli Lilly and Company Price History

15.07.2025 - LLY Stock was up 5.1%

• Eli Lilly stock climbed significantly today, driven by several factors:
• The UK monthly price increase for Mounjaro's highest dose and the pricing adjustment in India's Mounjaro Kwikpen likely contributed to the positive movement.
• Insider moves within the company, such as bold buys and record sales, may have boosted investor confidence.
• Speculation around undervalued healthcare stocks, including Eli Lilly, could have attracted buyers looking for potential growth opportunities.

26.07.2025 - LLY Stock was up 5.0%

• Eli Lilly stock surged after positive results from its oral GLP-1 pill trial, which demonstrated impressive weight loss benefits and blood sugar level reductions.
• The success of the weight-loss pill trial has fueled investor optimism and confidence in Eli Lilly's future growth prospects.
• Despite a setback with its orforglipron pill, the company's robust late-stage pipeline continues to support expectations for sustained growth and innovation in the pharmaceutical sector.
• The investigation by the Portnoy Law Firm into Eli Lilly's activities does not seem to have impacted the stock's bullish momentum, indicating that investors are primarily focused on the positive trial results and growth potential.

01.04.2025 - LLY Stock was down 10.7%

• A mix of results was reported by Eli Lilly for Q1, with earnings falling short of estimates while sales surpassed expectations, fueled by strong showings from Mounjaro and Zepbound.
• Despite a 45% increase in Q1 revenue and notable sales performance for key products, the stock saw a decrease, potentially linked to the revised 2025 profit projection tied to substantial IPR&D expenses.
• The market response to Eli Lilly's Q1 results may be connected to the disparity in earnings and revenue surprises, prompting scrutiny from investors about the company's future growth potential.
• Technical analysis pointed towards a bullish trajectory for Eli Lilly's stock; however, investor focus on the profit outlook and potential impact of IPR&D charges from the earnings report led to a bearish market response.

29.06.2025 - LLY Stock was down 5.2%

• The company witnessed a bearish movement in its stock performance.
• Reduced sales growth outlook of a competitor and concerns over illegal weight-loss drug imports impacting a specific drug category may have influenced overall market sentiment towards the company.
• Despite positive news of a drug recommendation for Alzheimer's disease, it may not have fully offset the prevailing negative market sentiment.
• The bearish stance taken by investors through options trading likely contributed to the stock's decline.

29.06.2025 - LLY Stock was down 6.1%

• The decline in Eli Lilly's stock could be linked to investors taking a bearish stance in options trading, as shown by publicly available options history.
• Concerns raised by Congress about the illegal import of weight-loss drugs from China, which also mentioned Eli Lilly, may have further dampened investor sentiment.
• While Eli Lilly received positive news of early Alzheimer's drug approval recommendation in Europe, the market seemed more influenced by general pessimism and regulatory risks.
• The conclusion of the Verve tender offer involving Eli Lilly likely impacted investor sentiment and contributed to the stock's bearish movement.

29.06.2025 - LLY Stock was down 6.7%

• The bearish movement in LLY stock could be attributed to concerns raised by Congress over illegal weight-loss drug imports from China, which might impact the company's reputation and sales.
• Despite the positive news of Eli Lilly's early Alzheimer's drug recommendation for approval in Europe, the market might be reacting more to the potential safety risks associated with illegal drug imports.
• Investors might be cautious about the upcoming Q2 earnings report, especially regarding the performance of Eli Lilly's oncology drugs, as any underperformance could have contributed to the bearish trend.
• The expiration of the Verve tender offer might also be a factor in the stock's movement, signaling potential shifts in the company's strategic partnerships or future developments.

15.06.2025 - LLY Stock was down 1.2%

• Deep-pocketed investors have recently taken a bearish approach towards Eli Lilly (LLY) options, which may have contributed to the stock's significant decline today.
• Despite the positive outlook for LLY's drugs like Mounjaro and Zepbound driving strong revenues, the bearish sentiment from market whales on the options front seems to have overshadowed the company's potential.
• The threat of 200% tariffs on pharmaceutical imports by President Trump could have also added to the overall bearish sentiment in the market, impacting stocks like Eli Lilly.
• While there were some bullish bets on Eli Lilly from other investors, the overall market movement today seems to have been influenced more by the bearish stance taken by market whales and external factors like trade tariffs.

16.04.2025 - LLY Stock was up 5.2%

• A recent 17% decline in LLY stock since Q1 results might have created a buying opportunity for investors seeking to benefit from the decrease.
• Despite concerns regarding its expensive valuation and declining estimates, the company's robust growth prospects are prompting investors to retain LLY stock.
• The bullish movement may be linked to investors reassessing Eli Lilly and Company's long-term potential, resulting in increased buying interest and driving up the stock price.

07.07.2025 - LLY Stock was down 13.3%

• Despite surpassing earnings and revenue estimates in Q2, Eli Lilly's stock experienced a bearish movement.
• The disappointment in the weight loss results of Orforglipron compared to financial forecasts may have contributed to the stock's decline.
• Threats of imposing high tariffs on pharmaceutical imports could have added uncertainty to the market, impacting Eli Lilly's stock negatively.
• The reversal of early weakness and the climb of 1.8% towards the end of the day could indicate some resilience in the stock, potentially driven by positive trading signals and smart money inflow.

08.06.2025 - LLY Stock was up 0.2%

• Eli Lilly has showcased impressive performance, outperforming the market substantially over the past decade, attracting investors seeking strong returns.
• Sales growth fueled by non-obesity drugs like Verzenio and Taltz highlights the company's diversified product portfolio and its ability to seize market opportunities across different drug categories.
• Positive sentiments from Wall Street analysts, with most recommending buying the stock, might have bolstered investor confidence in the company's future, contributing to the stock's bullish movement.
• Eli Lilly's robust market performance, promising sales growth, and favorable analyst outlook likely supported the bullish stock movement observed today.

06.04.2025 - LLY Stock was down 5.2%

• Cutting Eli Lilly's price target to $883 due to PBM-related uncertainty after CVS dropped Zepbound may have caused a lack of investor confidence, contributing to the bearish movement.
• Despite bullish options activity on Eli Lilly, concerns over the setback with CVS and missed earnings in Q1 might have overshadowed the positive sentiment.
• Mixed reactions from analysts and the market's response to the earnings miss despite strong revenue growth suggest investors are cautious about the company's future performance.
• The reduction in 2025 profit outlook, not due to tariffs but IPR&D charges, could have added to the negative sentiment surrounding Eli Lilly, leading to the bearish market movement.

17.06.2025 - LLY Stock was down 3.4%

• Eli Lilly's stock (LLY) faced a bearish trend, potentially influenced by concerns regarding its valuation despite a strong performance in the last decade.
• The negative stance taken by significant investors towards LLY options could have contributed to the stock's downward pressure.
• Even though drugs like Mounjaro and Zepbound hold promise for driving robust quarterly earnings, the prevailing market sentiment towards Eli Lilly was mostly unfavorable, resulting in the bearish movement.